HPV and cervical cancer

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 74, Issue SUPPL. 244, 2014, Pages 59-62

  Petry, Karl Ulrich ^a  

^a Klinikum der Stadt Wolfsburg   (Germany)

Author keywords

Human papilloma virus; Screening; Vaccination

Indexed keywords

CANCER IMMUNIZATION; CANCER PREVENTION; CANCER SCREENING; CELL POPULATION; CELL TRANSFORMATION; COHORT ANALYSIS; CONFERENCE PAPER; CYTOLOGY; FALSE POSITIVE RESULT; GOLD STANDARD; HUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; SMEAR; UTERINE CERVIX CANCER; WART VIRUS; EARLY DIAGNOSIS; FEMALE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIROLOGY;

EARLY DETECTION OF CANCER; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84905379460     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2014.936683     Document Type: Conference Paper

References (16)

1. Soerjomataram I, Lortet-Tieulent J, Parkin DM, et al. Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 2012; 380: 1840-50.
2. Arbyn M, Castellsague X, de Sanjosé S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011; 22: 2675-82.
3. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006; 24(Suppl. 3): S3/11-25.
4. Hildesheim A, Hadjmichael O, Schwartz P, et al. Risk factors for rapid onset cervical cancer. Am J Obstet Gynecol 1999; 180: 571-7.
5. Liebrich C, Brummer O, Von WR, et al. Primary cervical cancer truly negative for high-risk human papillomavirus is a rare but distinct entity that can affect virgins and young adolescents. Eur J Gynaecol Oncol 2009; 30: 45-8.
6. Herfs M, Yamamoto Y, Laur y A, et al. A discrete population of squamocolumnar junction cells implicated in the patho-genesis of cervical cancer. Proc Natl Acad Sci USA 2012; 109: 10516-21.
7. Petry KU, Luyten A, Justus A, et al. Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84-results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC Infect Dis 2013; 13: 135-46.
8. Wheeler CM, Castellsague X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 100-10.
9. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377: 2085-92.
10. Kocken M, Helmerhorst TJ, Berkhof J, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 2011; 12: 441-50.
11. Siebert U, Sroczynski G, Hillemanns P, et al. The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany. Eur J Public Health 2006; 16: 185-92.
12. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30(Suppl. 5): F88-99.
13. Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014; 383: 524-32.
14. TOMBOLA group: Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study. BMJ 2009; 339: b2549. doi: 10.1136/bmj.b2549 Accessed 12 May 2014 from: http://www.ncbi.nlm.nih.gov/pmc/ articles/PMC2718086/
15. Moss EL, Arbyn M, Dollery E, et al. European Federation of Colposcopy quality standards Delphi consultation. Eur J Obstet Gynecol Reprod Biol 2013; 170: 255-8.
16. Luyten A, Scherbring S, Reinecke-Luthge A, et al. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany-experience over 3 years. J Clin Virol 2009; 46(Suppl. 3): S5-10.